TILRAY, INC.

Bayer wins a significant case in Australia regarding glyphosate. Novo Nordisk adjusts stock target after a Phase-III study on weight loss drug Cagrisema disappoints. Deutsche Börse reports a trading volume of 1.31 trillion euros for 2024. Merck KGaA's stock shows minimal movement. Gilead Sciences upgraded by Morgan Stanley. Sanofi and GSK rated 'Outperform' by Bernstein Research. AbbVie cuts profit forecast due to higher costs. Canopy Growth stock recovers after hitting an all-time low. Roche stock rises significantly. STADA plans a billion-euro IPO. Eli Lilly and Novo Nordisk compete for top pharma stock in 2025. Merck & Co. to acquire WuXi Biologics' Irish vaccine facility for $500 million.

Celadon Pharmaceuticals faces a 40% stock drop due to funding delays, potentially running out of cash by January 2025. Meanwhile, Danish medical cannabis operators Stenocare and DanCann Pharma see stock spikes of over 50% after Denmark plans to make its medical cannabis scheme permanent. Tilray strengthens its position in Europe by launching the first German-grown medical cannabis flower.

Tilray advances in Europe with new cannabis licenses in Germany and product approvals in Portugal. Glass House Brands wins a lawsuit dismissal. GrowGeneration reports revenue growth despite store closures. Awakn updates on its psychedelic compound patents. Compass Pathways receives a positive rating from RBC for its psychedelic treatment research.